Unprecedented loss of life due to the COVID pandemic has necessitated the development of several vaccines in record time. Most of these vaccines have received approval without being extensively whetted for their adverse effect and efficacy profiles. Most adverse effects have been mild, nonetheless, more serious thromboembolic events have also been reported. Autoimmune hepatitis (AIH) can occur in predisposed individuals where an immune mediated reaction against hepatocytes is triggered by environmental factors. Vaccines are a very rare cause of AIH. We report two such cases of AIH triggered by COVID (Covishield) vaccination. While one patient made an uneventful recovery, another succumbed to the liver disease. Ours is the first report of Covishield vaccination related AIH and second ever after any form of COVID vaccination. We hope that our report does not deter COVID vaccination drives. However, we also hope to raise awareness of its potential side effects and the increased role of pharmacovigilance in guiding treatment.

由于 COVID 大流行造成前所未有的生命损失，因此有必要在创纪录的时间内开发多种疫苗。这些疫苗中的大多数已获得批准，但并未因其不良反应和功效特征而受到广泛关注。大多数不良反应都是轻微的，但也有更严重的血栓栓塞事件的报道。自身免疫性肝炎 (AIH) 可发生在易感个体中，其中环境因素触发了针对肝细胞的免疫介导反应。疫苗是 AIH 的一个非常罕见的原因。我们报告了两例由 COVID（Covishield）疫苗接种引发的 AIH 病例。一名患者顺利康复，另一名患者死于肝脏疾病。我们的报告是 Covishield 疫苗接种相关 AIH 的第一份报告，也是任何形式的 COVID 疫苗接种之后的第二份报告。我们希望我们的报告不会阻止 COVID 疫苗接种活动。然而，我们也希望提高对其潜在副作用的认识，以及药物警戒在指导治疗中的作用越来越大。